Irish journal of medical science · 2026
Elevated serum cardiotrophin-1 and interleukin-17 levels in psoriasis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sengul-Bag Fatma, Akyurek Fikret, Guven Halil, Tuncez-Akyurek Fatma
Аннотация
BACKGROUND: Psoriasis is a systemic, immune-mediated chronic disease in which the interleukin-23 (IL-23)/T-helper 17 (Th17) axis and its key effector cytokine, IL-17, play a central role. Cardiotrophin-1 (CT-1), a multifunctional cytokine from the IL-6 family, is involved in cardiovascular and metabolic homeostasis. This study aimed to evaluate serum levels of CT-1 and IL-17 in psoriasis, investigating their relationship with clinical parameters and their potential role as biomarkers for systemic inflammation and increased cardiometabolic risk.
METHODS: This study included 64 patients diagnosed with psoriasis vulgaris and 64 age- and sex-matched healthy controls. Serum CT-1 and IL-17 levels were measured using enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI).
RESULTS: Serum levels of both CT-1 and IL-17 were significantly higher in the psoriasis group compared to the control group (p < 0.001 for each). A strong positive correlation was found between the two cytokines (ρ = 0.890, p < 0.001). CT-1 showed stronger correlations with lipid parameters than IL-17. However, no significant correlation was observed for either cytokine with PASI or DLQI. Receiver operating characteristic (ROC) analysis demonstrated that CT-1 had stronger diagnostic accuracy (AUC: 0.915, 95% CI:0.869–0.961) for distinguishing psoriasis patients from healthy controls compared to IL-17 (AUC: 0.733, 95% CI:0.645–0.822).
CONCLUSIONS: This study shows that CT-1 and IL-17 levels are significantly elevated in psoriasis and suggests that this increase may be associated with systemic inflammation and dyslipidemia. The observed discriminative performance of CT-1 supports its potential relevance as a marker of systemic inflammatory and cardiometabolic involvement, although its clinical utility requires further clarification.
METHODS: This study included 64 patients diagnosed with psoriasis vulgaris and 64 age- and sex-matched healthy controls. Serum CT-1 and IL-17 levels were measured using enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI).
RESULTS: Serum levels of both CT-1 and IL-17 were significantly higher in the psoriasis group compared to the control group (p < 0.001 for each). A strong positive correlation was found between the two cytokines (ρ = 0.890, p < 0.001). CT-1 showed stronger correlations with lipid parameters than IL-17. However, no significant correlation was observed for either cytokine with PASI or DLQI. Receiver operating characteristic (ROC) analysis demonstrated that CT-1 had stronger diagnostic accuracy (AUC: 0.915, 95% CI:0.869–0.961) for distinguishing psoriasis patients from healthy controls compared to IL-17 (AUC: 0.733, 95% CI:0.645–0.822).
CONCLUSIONS: This study shows that CT-1 and IL-17 levels are significantly elevated in psoriasis and suggests that this increase may be associated with systemic inflammation and dyslipidemia. The observed discriminative performance of CT-1 supports its potential relevance as a marker of systemic inflammatory and cardiometabolic involvement, although its clinical utility requires further clarification.